143 related articles for article (PubMed ID: 12707459)
1. Severe intoxication after phenytoin infusion: a preventable pharmacogenetic adverse reaction.
Citerio G; Nobili A; Airoldi L; Pastorelli R; Patruno A
Neurology; 2003 Apr; 60(8):1395-6. PubMed ID: 12707459
[No Abstract] [Full Text] [Related]
2. Severe phenytoin toxicity in a CYP2C9*3*3 homozygous mutant from India.
Ramasamy K; Narayan SK; Chanolean S; Chandrasekaran A
Neurol India; 2007; 55(4):408-9. PubMed ID: 18040121
[TBL] [Abstract][Full Text] [Related]
3. Severe intoxication after phenytoin infusion: a preventable pharmacogenetic adverse reaction.
Lardizabal DV; Lüders HO; Hovinga CA; Bourgeois BF
Neurology; 2004 Jan; 62(1):161; author reply 161. PubMed ID: 14727316
[No Abstract] [Full Text] [Related]
4. Severe intoxication after phenytoin infusion: a preventable pharmacogenetic adverse reaction.
Privitera MD; Welty T
Neurology; 2004 Jan; 62(1):161; author reply 161. PubMed ID: 14718732
[No Abstract] [Full Text] [Related]
5. Acenocoumarol and phenytoin toxicity in the presence of CYP2C9 mutation.
Jose L; Binila C; Chandy SJ; Mathews JE; Mathews KP
J Assoc Physicians India; 2008 Apr; 56():250-2. PubMed ID: 18702389
[TBL] [Abstract][Full Text] [Related]
6. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions.
Chung WH; Chang WC; Lee YS; Wu YY; Yang CH; Ho HC; Chen MJ; Lin JY; Hui RC; Ho JC; Wu WM; Chen TJ; Wu T; Wu YR; Hsih MS; Tu PH; Chang CN; Hsu CN; Wu TL; Choon SE; Hsu CK; Chen DY; Liu CS; Lin CY; Kaniwa N; Saito Y; Takahashi Y; Nakamura R; Azukizawa H; Shi Y; Wang TH; Chuang SS; Tsai SF; Chang CJ; Chang YS; Hung SI; ;
JAMA; 2014 Aug; 312(5):525-34. PubMed ID: 25096692
[TBL] [Abstract][Full Text] [Related]
7. Phenytoin intoxication induced by fluvoxamine.
Mamiya K; Kojima K; Yukawa E; Higuchi S; Ieiri I; Ninomiya H; Tashiro N
Ther Drug Monit; 2001 Feb; 23(1):75-7. PubMed ID: 11206048
[TBL] [Abstract][Full Text] [Related]
8. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting.
Lee SY; Lee ST; Kim JW
J Biochem Mol Biol; 2007 May; 40(3):448-52. PubMed ID: 17562299
[TBL] [Abstract][Full Text] [Related]
9. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3.
Brandolese R; Scordo MG; Spina E; Gusella M; Padrini R
Clin Pharmacol Ther; 2001 Oct; 70(4):391-4. PubMed ID: 11673755
[TBL] [Abstract][Full Text] [Related]
10. CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes and phenytoin adverse reactions correlation.
Twardowschy CA; Werneck LC; Scola RH; De Paola L; Silvado CE
Arq Neuropsiquiatr; 2011 Apr; 69(2A):153-8. PubMed ID: 21537551
[TBL] [Abstract][Full Text] [Related]
11. Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy.
Lin CJ; Yen MF; Hu OY; Lin MS; Hsiong CH; Hung CC; Liou HH
Pharmacotherapy; 2008 Jan; 28(1):35-41. PubMed ID: 18154472
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics: reality or fiction? Or are we there yet?
Lopes-Cendes I; Guerreiro CA
Arq Neuropsiquiatr; 2011 Apr; 69(2A):151-2. PubMed ID: 21537550
[No Abstract] [Full Text] [Related]
13. Phenytoin toxicity due to genetic polymorphism.
McCluggage LK; Voils SA; Bullock MR
Neurocrit Care; 2009; 10(2):222-4. PubMed ID: 19030785
[TBL] [Abstract][Full Text] [Related]
14. The cytochrome P-450 2C9/2C19 but not the ABCB1 genetic polymorphism may be associated with the liver cytochrome 3A4 induction by phenytoin.
Chhun S; Verstuyft C; Rizzo-Padoin N; Simoneau G; Becquemont L; Bergmann JF; Mouly S
J Clin Psychopharmacol; 2012 Jun; 32(3):429-31. PubMed ID: 22561479
[No Abstract] [Full Text] [Related]
15. Use of multi-dose activated charcoal in phenytoin toxicity secondary to genetic polymorphism.
Chan BS; Sellors K; Chiew AL; Buckley NA
Clin Toxicol (Phila); 2015 Feb; 53(2):131-3. PubMed ID: 25597548
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine.
López M; Dorado P; Monroy N; Alonso ME; Jung-Cook H; Machín E; Peñas-Lledó E; Llerena A
Drug Metabol Drug Interact; 2011; 26(1):5-12. PubMed ID: 21557672
[TBL] [Abstract][Full Text] [Related]
17. Influence of CYP2C9 genetic polymorphism and undernourishment on plasma-free phenytoin concentrations in epileptic patients.
Ramasamy K; Narayan SK; Shewade DG; Chandrasekaran A
Ther Drug Monit; 2010 Dec; 32(6):762-6. PubMed ID: 21068649
[TBL] [Abstract][Full Text] [Related]
18. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity.
Depondt C; Godard P; Espel RS; Da Cruz AL; Lienard P; Pandolfo M
Eur J Neurol; 2011 Sep; 18(9):1159-64. PubMed ID: 21338443
[TBL] [Abstract][Full Text] [Related]
19. CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity.
Hennessy S; Leonard CE; Freeman CP; Metlay JP; Chu X; Strom BL; Bilker WB
J Clin Pharmacol; 2009 Dec; 49(12):1483-7. PubMed ID: 19617466
[No Abstract] [Full Text] [Related]
20. Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions.
Lee AY; Kim MJ; Chey WY; Choi J; Kim BG
Eur J Clin Pharmacol; 2004 May; 60(3):155-9. PubMed ID: 15024534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
